Skip to main content
PMC home page
Gut logoLink to Gut
. 2002 May;50(Suppl 3):iii43–iii46. doi: 10.1136/gut.50.suppl_3.iii43

New steroids and new salicylates in inflammatory bowel disease: a critical appraisal

M Campieri
PMCID: PMC1867683  PMID: 11953332

Full Text

The Full Text of this article is available as a PDF (82.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  2. Brignola C., Cottone M., Pera A., Ardizzone S., Scribano M. L., De Franchis R., D'Arienzo A., D'Albasio G., Pennestri D. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology. 1995 Feb;108(2):345–349. doi: 10.1016/0016-5085(95)90059-4. [DOI] [PubMed] [Google Scholar]
  3. Brignola C., De Simone G., Belloli C., Iannone P., Belluzzi A., Gionchetti P., Campieri M., Barbara L. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther. 1994 Aug;8(4):465–468. doi: 10.1111/j.1365-2036.1994.tb00316.x. [DOI] [PubMed] [Google Scholar]
  4. Campieri M., Cottone M., Miglio F., Manenti F., Astegiano M., D'Arienzo A., Manguso F., D'Albasio G., Bonanomi A., Galeazzi R. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther. 1998 Apr;12(4):361–366. doi: 10.1046/j.1365-2036.1998.00299.x. [DOI] [PubMed] [Google Scholar]
  5. Campieri M., Ferguson A., Doe W., Persson T., Nilsson L. G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997 Aug;41(2):209–214. doi: 10.1136/gut.41.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Campieri M., Gionchetti P., Belluzzi A., Brignola C., Tabanelli G. M., Miglioli M., Barbara L. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988 Aug;10(4):406–409. doi: 10.1097/00004836-198808000-00012. [DOI] [PubMed] [Google Scholar]
  7. Campieri M., Gionchetti P., Belluzzi A., Brignola C., Tampieri M., Iannone P., Miglioli M., Barbara L. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991 Aug;32(8):929–931. doi: 10.1136/gut.32.8.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Campieri M., Gionchetti P., Belluzzi A., Brignola C., Torresan F., Tampieri M., Iannone P., Miglioli M., Barbara L. 5-Aminosalicylic acid suppositories in the management of ulcerative colitis. Dis Colon Rectum. 1989 May;32(5):398–399. doi: 10.1007/BF02563691. [DOI] [PubMed] [Google Scholar]
  9. Campieri M., Lanfranchi G. A., Brignola C., Bazzocchi G., Gionchetti P., Minguzzi M. R., Cappello I. P., Corbelli C., Boschi S. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum. 1986 Feb;29(2):108–110. doi: 10.1007/BF02555391. [DOI] [PubMed] [Google Scholar]
  10. Caprilli R., Andreoli A., Capurso L., Corrao G., D'Albasio G., Gioieni A., Assuero Lanfranchi G., Paladini I., Pallone F., Ponti V. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther. 1994 Feb;8(1):35–43. doi: 10.1111/j.1365-2036.1994.tb00158.x. [DOI] [PubMed] [Google Scholar]
  11. Cohen R. D., Woseth D. M., Thisted R. A., Hanauer S. B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May;95(5):1263–1276. doi: 10.1111/j.1572-0241.2000.01940.x. [DOI] [PubMed] [Google Scholar]
  12. Cortot A., Colombel J. F., Rutgeerts P., Lauritsen K., Malchow H., Hämling J., Winter T., Van Gossum A, Persson T., Pettersson E. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut. 2001 Feb;48(2):186–190. doi: 10.1136/gut.48.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cottone M., Cammà C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology. 2000 Aug;119(2):597–597. doi: 10.1053/gast.2000.16153. [DOI] [PubMed] [Google Scholar]
  14. Cottone M., Cammà C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology. 2000 Aug;119(2):597–597. doi: 10.1053/gast.2000.16153. [DOI] [PubMed] [Google Scholar]
  15. Gendre J. P., Mary J. Y., Florent C., Modigliani R., Colombel J. F., Soulé J. C., Galmiche J. P., Lerebours E., Descos L., Viteau J. M. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology. 1993 Feb;104(2):435–439. doi: 10.1016/0016-5085(93)90411-5. [DOI] [PubMed] [Google Scholar]
  16. Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Miglioli M., Campieri M. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998 Jan;41(1):93–97. doi: 10.1007/BF02236902. [DOI] [PubMed] [Google Scholar]
  17. Green J. R., Gibson J. A., Kerr G. D., Swarbrick E. T., Lobo A. J., Holdsworth C. D., Crowe J. P., Schofield K. J., Taylor M. D. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther. 1998 Dec;12(12):1207–1216. doi: 10.1046/j.1365-2036.1998.00427.x. [DOI] [PubMed] [Google Scholar]
  18. Green J. R., Lobo A. J., Holdsworth C. D., Leicester R. J., Gibson J. A., Kerr G. D., Hodgson H. J., Parkins K. J., Taylor M. D. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998 Jan;114(1):15–22. doi: 10.1016/s0016-5085(98)70627-4. [DOI] [PubMed] [Google Scholar]
  19. Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996 Jan;110(1):45–51. doi: 10.1053/gast.1996.v110.pm8536887. [DOI] [PubMed] [Google Scholar]
  20. Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994 Sep 29;331(13):836–841. doi: 10.1056/NEJM199409293311303. [DOI] [PubMed] [Google Scholar]
  21. Hellers G., Cortot A., Jewell D., Leijonmarck C. E., Löfberg R., Malchow H., Nilsson L. G., Pallone F., Pena S., Persson T. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999 Feb;116(2):294–300. doi: 10.1016/s0016-5085(99)70125-3. [DOI] [PubMed] [Google Scholar]
  22. Lochs H., Mayer M., Fleig W. E., Mortensen P. B., Bauer P., Genser D., Petritsch W., Raithel M., Hoffmann R., Gross V. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000 Feb;118(2):264–273. doi: 10.1016/s0016-5085(00)70208-3. [DOI] [PubMed] [Google Scholar]
  23. Löfberg R., Danielsson A., Salde L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther. 1993 Dec;7(6):611–616. doi: 10.1111/j.1365-2036.1993.tb00141.x. [DOI] [PubMed] [Google Scholar]
  24. Löfberg R., Rutgeerts P., Malchow H., Lamers C., Danielsson A., Olaison G., Jewell D., Ostergaard Thomsen O., Lorenz-Meyer H., Goebell H. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996 Jul;39(1):82–86. doi: 10.1136/gut.39.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Malchow H., Ewe K., Brandes J. W., Goebell H., Ehms H., Sommer H., Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984 Feb;86(2):249–266. [PubMed] [Google Scholar]
  26. Marshall J. K., Irvine E. J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000 Jul;95(7):1628–1636. doi: 10.1111/j.1572-0241.2000.02180.x. [DOI] [PubMed] [Google Scholar]
  27. Marshall J. K., Irvine E. J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther. 1995 Jun;9(3):293–300. doi: 10.1111/j.1365-2036.1995.tb00384.x. [DOI] [PubMed] [Google Scholar]
  28. Marshall J. K., Irvine E. J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997 Jun;40(6):775–781. doi: 10.1136/gut.40.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. McLeod R. S., Wolff B. G., Steinhart A. H., Carryer P. W., O'Rourke K., Andrews D. F., Blair J. E., Cangemi J. R., Cohen Z., Cullen J. B. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995 Aug;109(2):404–413. doi: 10.1016/0016-5085(95)90327-5. [DOI] [PubMed] [Google Scholar]
  30. Modigliani R., Mary J. Y., Simon J. F., Cortot A., Soule J. C., Gendre J. P., Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990 Apr;98(4):811–818. doi: 10.1016/0016-5085(90)90002-i. [DOI] [PubMed] [Google Scholar]
  31. Mulder C. J., Fockens P., Meijer J. W., van der Heide H., Wiltink E. H., Tytgat G. N. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996 Jun;8(6):549–553. doi: 10.1097/00042737-199606000-00010. [DOI] [PubMed] [Google Scholar]
  32. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994 Mar;35(3):360–362. doi: 10.1136/gut.35.3.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rutgeerts P., Löfberg R., Malchow H., Lamers C., Olaison G., Jewell D., Danielsson A., Goebell H., Thomsen O. O., Lorenz-Meyer H. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 Sep 29;331(13):842–845. doi: 10.1056/NEJM199409293311304. [DOI] [PubMed] [Google Scholar]
  34. Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., Koval G., Nichols T., Targan S., Fleishman C. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997 Oct;92(10):1867–1871. [PubMed] [Google Scholar]
  35. Summers R. W., Switz D. M., Sessions J. T., Jr, Becktel J. M., Best W. R., Kern F., Jr, Singleton J. W. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979 Oct;77(4 Pt 2):847–869. [PubMed] [Google Scholar]
  36. Sutherland L. R., Martin F., Bailey R. J., Fedorak R. N., Poleski M., Dallaire C., Rossman R., Saibil F., Lariviere L. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology. 1997 Apr;112(4):1069–1077. doi: 10.1016/s0016-5085(97)70117-3. [DOI] [PubMed] [Google Scholar]
  37. Thomsen O. O., Cortot A., Jewell D., Wright J. P., Winter T., Veloso F. T., Vatn M., Persson T., Pettersson E. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998 Aug 6;339(6):370–374. doi: 10.1056/NEJM199808063390603. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES